Intrinsic value of NantKwest - NK

Previous Close

$2.31

  Intrinsic Value

$0.69

stock screener

  Rating & Target

str. sell

-70%

Previous close

$2.31

 
Intrinsic value

$0.69

 
Up/down potential

-70%

 
Rating

str. sell

We calculate the intrinsic value of NK stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Variable operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Fixed operating expenses, $m
  104
  107
  109
  111
  114
  116
  119
  121
  124
  127
  130
  132
  135
  138
  141
  144
  148
  151
  154
  158
  161
  165
  168
  172
  176
  180
  184
  188
  192
  196
Total operating expenses, $m
  104
  107
  109
  111
  114
  116
  119
  121
  124
  127
  130
  132
  135
  138
  141
  144
  147
  150
  153
  157
  160
  164
  167
  171
  175
  179
  183
  187
  191
  195
Operating income, $m
  -104
  -106
  -109
  -111
  -114
  -116
  -119
  -121
  -124
  -127
  -129
  -132
  -135
  -138
  -141
  -144
  -147
  -150
  -154
  -157
  -160
  -164
  -167
  -171
  -175
  -179
  -183
  -187
  -191
  -195
EBITDA, $m
  -104
  -106
  -109
  -111
  -113
  -116
  -118
  -121
  -124
  -126
  -129
  -132
  -135
  -138
  -141
  -144
  -147
  -150
  -154
  -157
  -160
  -164
  -167
  -171
  -175
  -179
  -183
  -187
  -191
  -195
Interest expense (income), $m
  0
  1
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -10
Earnings before tax, $m
  -105
  -97
  -99
  -101
  -104
  -106
  -109
  -111
  -114
  -117
  -119
  -122
  -125
  -128
  -131
  -134
  -137
  -140
  -144
  -147
  -151
  -154
  -158
  -161
  -165
  -169
  -173
  -177
  -181
  -185
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -105
  -97
  -99
  -101
  -104
  -106
  -109
  -111
  -114
  -117
  -119
  -122
  -125
  -128
  -131
  -134
  -137
  -140
  -144
  -147
  -151
  -154
  -158
  -161
  -165
  -169
  -173
  -177
  -181
  -185

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Adjusted assets (=assets-cash), $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Revenue / Adjusted assets
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
Average production assets, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Working capital, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total debt, $m
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
  -30
Total liabilities, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total equity, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total liabilities and equity, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Debt-to-equity ratio
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
Adjusted equity ratio
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000
  0.000

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -105
  -97
  -99
  -101
  -104
  -106
  -109
  -111
  -114
  -117
  -119
  -122
  -125
  -128
  -131
  -134
  -137
  -140
  -144
  -147
  -151
  -154
  -158
  -161
  -165
  -169
  -173
  -177
  -181
  -185
Depreciation, amort., depletion, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Funds from operations, $m
  -104
  -96
  -99
  -101
  -104
  -106
  -109
  -111
  -114
  -117
  -119
  -122
  -125
  -128
  -131
  -134
  -137
  -140
  -144
  -147
  -151
  -154
  -158
  -161
  -165
  -169
  -173
  -177
  -181
  -185
Change in working capital, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from operations, $m
  -104
  -96
  -99
  -101
  -104
  -106
  -109
  -111
  -114
  -117
  -119
  -122
  -125
  -128
  -131
  -134
  -137
  -140
  -144
  -147
  -151
  -154
  -158
  -161
  -165
  -169
  -173
  -177
  -181
  -185
Maintenance CAPEX, $m
  -5
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
New CAPEX, $m
  50
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from investing activities, $m
  45
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Free cash flow, $m
  -60
  -96
  -99
  -101
  -104
  -106
  -109
  -111
  -114
  -117
  -119
  -122
  -125
  -128
  -131
  -134
  -137
  -140
  -144
  -147
  -151
  -154
  -158
  -161
  -165
  -169
  -173
  -177
  -181
  -185
Issuance/(repayment) of debt, $m
  -32
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Issuance/(repurchase) of shares, $m
  -112
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -144
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total cash flow (excl. dividends), $m
  -203
  -96
  -99
  -101
  -104
  -106
  -109
  -111
  -114
  -117
  -119
  -122
  -125
  -128
  -131
  -134
  -137
  -140
  -144
  -147
  -151
  -154
  -158
  -161
  -165
  -169
  -173
  -177
  -181
  -185
Retained Cash Flow (-), $m
  7
  -97
  -99
  -101
  -104
  -106
  -109
  -111
  -114
  -117
  -119
  -122
  -125
  -128
  -131
  -134
  -137
  -140
  -144
  -147
  -151
  -154
  -158
  -161
  -165
  -169
  -173
  -177
  -181
  -185
Prev. year cash balance distribution, $m
  107
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  7
  -97
  -99
  -101
  -104
  -106
  -109
  -111
  -114
  -117
  -119
  -122
  -125
  -128
  -131
  -134
  -137
  -140
  -144
  -147
  -151
  -154
  -158
  -161
  -165
  -169
  -173
  -177
  -181
  -185
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  7
  -89
  -86
  -83
  -80
  -77
  -74
  -70
  -66
  -61
  -57
  -52
  -48
  -43
  -38
  -34
  -30
  -26
  -22
  -19
  -16
  -13
  -10
  -8
  -6
  -5
  -4
  -3
  -2
  -1
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.

FINANCIAL RATIOS  of  NantKwest (NK)

Valuation Ratios
P/E Ratio -1.6
Price to Sales 0
Price to Book 0.6
Price to Tangible Book
Price to Cash Flow -4.9
Price to Free Cash Flow -4.1
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 250%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0.7%
Total Debt to Equity 0.7%
Interest Coverage 0
Management Effectiveness
Return On Assets -35.3%
Ret/ On Assets - 3 Yr. Avg. -55.2%
Return On Total Capital -37.2%
Ret/ On T. Cap. - 3 Yr. Avg. -57.6%
Return On Equity -37.3%
Return On Equity - 3 Yr. Avg. -57.9%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. -200%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. -166.7%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. -200%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. -200%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

NK stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NK stock intrinsic value calculation we used $0.045 million for the last fiscal year's total revenue generated by NantKwest. The default revenue input number comes from 0001 income statement of NantKwest. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NK stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for NK is calculated based on our internal credit rating of NantKwest, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of NantKwest.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NK stock the variable cost ratio is equal to 0%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $102 million in the base year in the intrinsic value calculation for NK stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 32.8% for NantKwest.

Corporate tax rate of 27% is the nominal tax rate for NantKwest. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NK stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NK are equal to 0%.

Life of production assets of 9.3 years is the average useful life of capital assets used in NantKwest operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NK is equal to 0%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $218.844 million for NantKwest - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 78.088 million for NantKwest is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of NantKwest at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
XON Intrexon 10.31 0.27  str.sell
CELG Celgene 69.98 340.31  str.buy
AMGN Amgen 192.45 130.16  sell
BLCM Bellicum Pharm 4.49 1.25  str.sell
BLUE bluebird bio 122.78 7.95  str.sell
IMDZ Immune Design 1.42 0.72  str.sell

COMPANY NEWS

▶ Here's Why NantKwest Skyrocketed 26.4% Today   [Nov-08-18 12:56PM  Motley Fool]
▶ Who Are The Top Investors In NantKwest Inc (NASDAQ:NK)?   [Sep-18-18 01:52PM  Simply Wall St.]
▶ NantKwest Names Sonja Nelson Chief Financial Officer   [Jun-19-18 05:00AM  Business Wire]
▶ Rockville biotech founded by L.A. billionaire to lay off 52   [02:49PM  American City Business Journals]
▶ Putin says U.S. is taking 'hostile step'   [Jan-30-18 09:06AM  Yahoo Finance]
▶ Yahoo Finance Live: Market Movers - Jan 30th, 2018   [07:20AM  Yahoo Finance Video]
▶ 3 Stocks Under $10 That Surged Yesterday   [Jan-24-18 02:05PM  InvestorPlace]
▶ 3 Stocks Under $10 That Surged Today   [Jan-23-18 06:44PM  Zacks]
▶ ETFs with exposure to NantKwest, Inc. : December 28, 2017   [Dec-28-17 12:30PM  Capital Cube]
▶ ETFs with exposure to NantKwest, Inc. : October 11, 2017   [Oct-11-17 11:52AM  Capital Cube]
▶ ETFs with exposure to NantKwest, Inc. : August 31, 2017   [Aug-31-17 07:38PM  Capital Cube]
▶ Here's Why NantKwest Inc. Tumbled 21.1% in July   [Aug-09-17 11:50AM  Motley Fool]
▶ How to Uncover Institutional Buying   [Jun-20-17 05:37PM  Zacks]
▶ ETFs with exposure to NantKwest, Inc. : June 19, 2017   [Jun-19-17 03:48PM  Capital Cube]
▶ 2 Longs And 2 Shorts To Watch   [Jun-14-17 02:09PM  Benzinga]
▶ Biotech Movers: Cerus, Alexion, NantKwest   [May-23-17 09:29AM  TheStreet.com]
▶ Why Rite Aid, H&R Block, and NantKwest Slumped Today   [May-16-17 05:02PM  Motley Fool]
▶ Why NantKwest Stock Is Spiking Today   [02:34PM  Motley Fool]
▶ NantKwest reports 1Q loss   [06:00AM  Associated Press]
▶ ETFs with exposure to NantKwest, Inc. : May 4, 2017   [May-04-17 04:11PM  Capital Cube]
▶ ETFs with exposure to NantKwest, Inc. : April 24, 2017   [Apr-24-17 02:37PM  Capital Cube]
▶ ETFs with exposure to NantKwest, Inc. : April 7, 2017   [Apr-07-17 05:08PM  Capital Cube]
▶ ETFs with exposure to NantKwest, Inc. : March 27, 2017   [Mar-27-17 04:01PM  Capital Cube]
▶ NantKwest to Present at Upcoming Investor Conferences   [Mar-06-17 05:00AM  Business Wire]
▶ How Nantkwest Inc (NK) Stacks Up Versus Peers   [12:13AM  at Insider Monkey]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.